Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Reports Q2 Revenue Gains

NEW YORK, Aug. 5 (GenomeWeb News) - Caliper Life Sciences today reported a 222 percent gain in second-quarter revenues, driven by sales from Zymark, which the firm acquired in July 2003.

 

Caliper had revenues of $18.9 million in the quarter, up from $5.9 million in the second quarter of 2003.

 

The Hopkinton, Mass.-based firm posted a net loss of $9.5 million, or $.33 per share, compared to a net loss of $9.5 million, or $.38 per share, in the comparable period last year. This year's second-quarter results include a $2.4 million restructuring charge related to future lease costs of facilities no longer occupied following consolidation of its Mountain View, Calif., operations. The results also included $180,000 in severance charges and related benefits incurred in connection with the elimination of 14 positions.

 

Caliper finished the quarter with $52.9 million in cash, equivalents and short-term marketable securities.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.